{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:02:36Z","timestamp":1784332956492,"version":"3.55.0"},"reference-count":26,"publisher":"Georg Thieme Verlag KG","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Thromb Hemost"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Treatment of catheter-related thrombosis (CRT) in acute leukemia patients is challenging due to concomitant thrombocytopenia. Although modified-dose anticoagulation is frequently used in this setting, several vital outcomes remain unclear. The current study evaluated clinical outcomes of a platelet-count-guided low molecular weight heparin (LMWH) regimen in these patients. Data on all newly diagnosed acute leukemia patients, who developed CRT, were retrieved from the institutional database. Upon CRT diagnosis, patients received either a full or modified dose of LMWH, based on their platelet counts. Outcomes included recurrent venous thromboembolism (VTE), hemorrhagic events. Competing risk analyses were performed, with death considered a competing risk. All-cause mortality and blood product utilization (per patient; pre- and postanticoagulation commencement) were compared. A total of 193 acute leukemia patients diagnosed with CRT between November 2004 and May 2022 were included. Eighty-seven patients (45%) received full-dose LMWH. Modified-dose LMWH treatment was associated with hazard ratio (HR) of 0.642 (95% confidence interval [CI]: 0.268\u20131.540; p\u2009=\u20090.320) in terms of CRT recurrence and HR of 0.975 (95% CI: 0.439\u20132.170; p\u2009=\u20090.950) in terms of hemorrhage. Mortality was not significantly higher in the modified-dose group (HR: 1.47, 95% CI: 0.93\u20132.32; p\u2009=\u20090.092). Notably, platelet requirement did not differ before and after the CRT diagnosis, irrespective of LMWH doses used (full-dose group: median pre-CRT 0.09 [interquartile range, IQR: 0\u20130.27] vs. post-CRT 0.05 [IQR: 0.01\u20130.14] units\/day, p\u2009=\u20090.059; modified-dose group: median pre-CRT 0.03 [IQR: 0\u20130.24] vs. post-CRT 0.07 [IQR: 0.01\u20130.18] units\/day, p\u2009=\u20090.720). In acute leukemia patients with CRT, a platelet-count-guided LMWH regimen was not associated with higher rates of recurrent VTE, hemorrhagic complications, mortality, or platelet transfusion requirements.<\/jats:p>","DOI":"10.1055\/a-2905-4225","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T23:07:01Z","timestamp":1784329621000},"source":"Crossref","is-referenced-by-count":0,"title":["Platelet-Count-Guided Low Molecular Weight Heparin Management of Catheter-Related Thrombosis in a Large Cohort of Patients with Newly Diagnosed Acute Leukemia"],"prefix":"10.1055","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7280-4062","authenticated-orcid":false,"given":"Shay","family":"Perek","sequence":"first","affiliation":[{"name":"Rambam Health Care Campus, Israel","place":["Haifa"],"department":["Department of Emergency Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niv","family":"Izhaki","sequence":"first","affiliation":[{"name":"Rambam Health Care Campus, Israel","place":["Haifa"],"department":["Department of Emergency Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Hoffman","sequence":"additional","affiliation":[{"name":"Rambam Health Care Campus, Israel","place":["Haifa"],"department":["Department of Hematology and Bone Marrow Transplantation"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7076-6501","authenticated-orcid":false,"given":"Benjamin","family":"Brenner","sequence":"additional","affiliation":[{"name":"Rambam Health Care Campus, Israel","place":["Haifa"],"department":["Department of Hematology and Bone Marrow Transplantation"]},{"name":"Technion Israel Institute of Technology, Israel","place":["Haifa"],"department":["The Ruth and Bruce Rappaport Faculty of Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Netanel A.","family":"Horowitz","sequence":"additional","affiliation":[{"name":"Rambam Health Care Campus, Israel","place":["Haifa"],"department":["Department of Hematology and Bone Marrow Transplantation"]},{"name":"Technion Israel Institute of Technology, Israel","place":["Haifa"],"department":["The Ruth and Bruce Rappaport Faculty of Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.blre.2018.06.002","article-title":"Venous thromboembolism incidence in hematologic malignancies","volume":"33","author":"N Kekre","year":"2019","journal-title":"Blood Rev"},{"issue":"06","key":"ref2","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/CCO.0000000000000402","article-title":"Thrombosis in adult patients with acute leukemia","volume":"29","author":"M I Del Principe","year":"2017","journal-title":"Curr Opin Oncol"},{"issue":"10","key":"ref3","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1200\/JCO.2012.45.5733","article-title":"Central venous catheter care for the patient with cancer: American Society of Clinical Oncology clinical practice guideline","volume":"31","author":"C A Schiffer","year":"2013","journal-title":"J Clin Oncol"},{"issue":"S 05","key":"ref4","doi-asserted-by":"crossref","first-page":"v152","DOI":"10.1093\/annonc\/mdv296","article-title":"Central venous access in oncology: ESMO Clinical Practice Guidelines","volume":"26","author":"B Sousa","year":"2015","journal-title":"Ann Oncol"},{"issue":"06","key":"ref5","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/j.1365-2141.2005.05529.x","article-title":"Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study","volume":"129","author":"A Cortelezzi","year":"2005","journal-title":"Br J Haematol"},{"issue":"17","key":"ref6","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1182\/blood-2008-08-175745","article-title":"Venous thromboembolism in patients with acute leukemia: incidence, risk factors, and effect on survival","volume":"113","author":"G H Ku","year":"2009","journal-title":"Blood"},{"issue":"01","key":"ref7","doi-asserted-by":"crossref","first-page":"e14311","DOI":"10.1111\/eci.14311","article-title":"Catheter-related deep vein thrombosis: where are we at and where are we going? Updates and ongoing unmet clinical needs","volume":"55","author":"L Girardi","year":"2025","journal-title":"Eur J Clin Invest"},{"issue":"12","key":"ref8","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1007\/s00277-016-2798-4","article-title":"Incidence of catheter-related thrombosis in acute leukemia patients: a comparative, retrospective study of the safety of peripherally inserted vs. centrally inserted central venous catheters","volume":"95","author":"M Refaei","year":"2016","journal-title":"Ann Hematol"},{"issue":"03","key":"ref9","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1046\/j.1365-2141.2003.04638.x","article-title":"Central venous catheter related thrombosis in haematology patients and prediction of risk by screening with Doppler-ultrasound","volume":"123","author":"C J van Rooden","year":"2003","journal-title":"Br J Haematol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.thromres.2021.03.021","article-title":"Treatment of catheter-related thrombosis in patients with hematologic malignancies: a Venous thromboEmbolism Network U.S. retrospective cohort study","volume":"202","author":"L Baumann Kreuziger","year":"2021","journal-title":"Thromb Res"},{"issue":"03","key":"ref11","first-page":"171","article-title":"(see Appendix 1) Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensus","volume":"17","author":"M Napolitano","year":"2019","journal-title":"Blood Transfus"},{"issue":"02","key":"ref12","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00277-014-2198-6","article-title":"Management and outcomes of cancer-associated venous thromboembolism in patients with concomitant thrombocytopenia: a retrospective cohort study","volume":"94","author":"I Kopolovic","year":"2015","journal-title":"Ann Hematol"},{"issue":"07","key":"ref13","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.3109\/10428194.2014.982640","article-title":"Treatment of catheter-related deep vein thrombosis in patients with acute leukemia with anticoagulation","volume":"56","author":"N Oliver","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"03","key":"ref14","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s11239-018-1711-5","article-title":"Incidence and outcomes of catheter related thrombosis (CRT) in patients with acute leukemia using a platelet-adjusted low molecular weight heparin regimen","volume":"46","author":"K T Htun","year":"2018","journal-title":"J Thromb Thrombolysis"},{"issue":"06","key":"ref15","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/jth.14015","article-title":"Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH","volume":"16","author":"B T Samuelson Bannow","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref16","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s11239-020-02040-8","article-title":"PICC-related upper deep venous thrombosis in patients with hematological malignancies. Management of anticoagulant therapy according to the platelet count","volume":"49","author":"M C Scamuffa","year":"2020","journal-title":"J Thromb Thrombolysis"},{"issue":"07","key":"ref17","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1016\/S1470-2045(22)00160-7","article-title":"2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19","volume":"23","author":"D Farge","year":"2022","journal-title":"Lancet Oncol"},{"issue":"07","key":"ref19","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1056\/NEJMoa0904084","article-title":"Dose of prophylactic platelet transfusions and prevention of hemorrhage","volume":"362","author":"S J Slichter","year":"2010","journal-title":"N Engl J Med"},{"issue":"07","key":"ref20","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.3390\/cancers15072147","article-title":"Intravascular complications of central venous catheterization by insertion site in acute leukemia during remission induction chemotherapy phase: lower risk with peripherally inserted catheters in a single-center retrospective study","volume":"15","author":"M Picardi","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"02","key":"ref21","first-page":"1673","article-title":"A prospective study of the use of central venous catheters in patients newly diagnosed with acute myeloid leukemia treated with induction chemotherapy","volume":"30","author":"C McKeown","year":"2022","journal-title":"Support Care Cancer"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejim.2022.04.025","article-title":"A prediction model for central venous catheter-related thrombosis in patients with newly-diagnosed acute myeloid leukemia: a derivation cohort analysis","volume":"101","author":"S Perek","year":"2022","journal-title":"Eur J Intern Med"},{"issue":"01","key":"ref23","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11739-021-02771-3","article-title":"Current management of cancer-associated venous thromboembolism in patients with thrombocytopenia: a retrospective cohort study","volume":"17","author":"A Squizzato","year":"2022","journal-title":"Intern Emerg Med"},{"issue":"24","key":"ref24","doi-asserted-by":"crossref","first-page":"5546","DOI":"10.1182\/bloodadvances.2021005966","article-title":"Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multicenter cohort study","volume":"5","author":"B J Carney","year":"2021","journal-title":"Blood Adv"},{"issue":"11","key":"ref25","doi-asserted-by":"crossref","first-page":"E468","DOI":"10.1002\/ajh.24526","article-title":"Venous thromboembolism in patients with hematologic malignancy and thrombocytopenia","volume":"91","author":"N Khanal","year":"2016","journal-title":"Am J Hematol"},{"issue":"19","key":"ref26","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.1002\/cncr.31674","article-title":"Adult leukemia survival trends in the United States by subtype: a population-based registry study of 370,994 patients diagnosed during 1995-2009","volume":"124","author":"C Bailey","year":"2018","journal-title":"Cancer"},{"issue":"02","key":"ref27","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s40121-021-00433-7","article-title":"Fatal infections among cancer patients: a population-based study in the United States","volume":"10","author":"Y Zheng","year":"2021","journal-title":"Infect Dis Ther"}],"container-title":["Seminars in Thrombosis and Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2905-4225.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T23:07:04Z","timestamp":1784329624000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2905-4225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":26,"URL":"https:\/\/doi.org\/10.1055\/a-2905-4225","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0094-6176","1098-9064"],"issn-type":[{"value":"0094-6176","type":"print"},{"value":"1098-9064","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]}}}